Metformina + Sitagliptina Ciclum

Metformin Hydrochloride and Sitagliptin, the active ingredients in Metformina + Sitagliptina Ciclum, are a combination of a biguanide and a DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults, helping to control blood glucose levels alongside diet and exercise.

GNH USA supplies Metformina + Sitagliptina Ciclum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Sitagliptina Ciclum is indicated for the management of type 2 diabetes mellitus, acting on glucose regulation pathways. - Type 2 diabetes mellitus: improves glycemic control when added to diet, exercise and other antidiabetic agents. - Inadequate control on metformin alone: provides additional glucose‑lowering effect as part of combination therapy. - Adults requiring combination therapy: offers a single‑pill option to simplify treatment regimens.

The following adverse reactions have been reported with the combination of metformin and sitagliptin.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: frequent loose stools, usually transient. - Abdominal discomfort: cramping or pain. - Headache: mild to moderate intensity. - Upper respiratory tract infection: symptoms of cold or flu. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic failure: marked liver dysfunction. - Renal impairment worsening: decline in kidney function.

When prescribing Metformina + Sitagliptina Ciclum, clinicians should consider several safety aspects. - Renal function assessment: avoid or adjust dose in patients with impaired renal function. - Hepatic disease monitoring: use with caution in liver disease due to lactic acidosis risk. - Risk of hypoglycaemia: monitor when combined with insulin or sulfonylureas. - Pregnancy and lactation: generally not recommended; evaluate risk‑benefit. - Contraindications: do not use in patients with known hypersensitivity to either component. - Store below 25°C: keep in the original pack, protect from moisture.

Metformina + Sitagliptina Ciclum may interact with several medications, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate metformin‑associated lactic acidosis. - Insulin secretagogues (e.g., sulfonylureas): increase risk of severe hypoglycaemia. - Strong CYP3A4 inhibitors: may raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Cimetidine: can increase sitagliptin exposure. - Diuretics and ACE inhibitors: may affect renal function, altering metformin clearance. - NSAIDs: can impair renal function, increasing metformin accumulation risk. - Warfarin: monitor INR as glycaemic changes may affect anticoagulation.